Eyenovia Appoints Andrew Jones as New Chief Financial Officer
Eyenovia, Inc. (NASDAQ: EYEN), a leading player in the ophthalmic industry, has announced the appointment of Andrew Jones as its new Chief Financial Officer. Mr. Jones brings over 30 years of extensive experience in finance and accounting, particularly in the fields of therapeutics and medical technology. His most recent position was as CFO at NovaBay Pharmaceuticals, where he played a key role in driving the company’s growth.
Leadership Transition
This strategic move comes as the current CFO, John Gandolfo, is set to retire. Gandolfo will continue to support Eyenovia until November to ensure a smooth transition. Michael Rowe, Eyenovia's Chief Executive Officer, expressed his excitement about Mr. Jones joining the team, noting that his vast experience aligns perfectly with the company’s current developmental phase.
Looking Ahead
With important milestones on the horizon, such as a major data readout for MicroPine and the U.S. launch of clobetasol, Mr. Jones' skills in operations and capital raising will be crucial. CEO Rowe emphasized the importance of this role in positioning the company for ongoing success.
About Andrew Jones
Prior to his role at Eyenovia, Mr. Jones was instrumental at NovaBay Pharmaceuticals, where he directed financial strategies during a significant growth phase. He also served as Vice President of Finance at MyoScience, where he helped successfully commercialize a pain management device. His extensive experience includes serving as a Controller for multiple life sciences organizations, and he began his career at PricewaterhouseCoopers.
Strategic Vision
Andrew Jones expressed his enthusiasm for joining Eyenovia, highlighting the company’s commercial strategy and the opportunity to expand Optejet technology to address a range of ophthalmic needs. His vision is well-aligned with Eyenovia’s commitment to innovation in ophthalmic medications.
The Eyenovia Mission
Eyenovia, Inc. is dedicated to advancing the treatment of various ophthalmic conditions through its innovative microdose array print therapeutics. The company is currently focused on the FDA-approved MYDCOMBI for mydriasis and clobetasol propionate ophthalmic suspension for post-surgical applications. Eyenovia is also committed to developing new therapies to address pediatric progressive myopia.
Commitment to Growth and Improvement
As part of its growth strategy, Eyenovia actively pursues various collaboration agreements that could enhance the application of its unique technologies. The company remains dedicated to creating long-term value within the ophthalmic market.
Frequently Asked Questions
Who is the new CFO of Eyenovia?
Andrew Jones has been appointed as the new Chief Financial Officer of Eyenovia, Inc.
What experience does Andrew Jones bring to Eyenovia?
Andrew Jones brings over 30 years of finance and accounting leadership, with extensive experience in the therapeutics and medical technology sectors.
What is the significance of the CFO transition?
The transition marks a crucial period as Eyenovia is poised for significant product launches and data readouts in the near future.
How does Eyenovia plan to grow in the ophthalmic market?
Eyenovia focuses on innovating and expanding its product offerings while actively pursuing strategic collaborations.
What products is Eyenovia currently developing?
Currently, Eyenovia is commercializing MYDCOMBI and clobetasol propionate while developing additional therapies for pediatric progressive myopia.
